BFM
AUPH icon

Boothbay Fund Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Boothbay Fund Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,000
Closed -$126K – 1720
2023
Q2 		$126K Sell
13,000
-3,400
-21% -$35.3K ﹤0.01% 1576
2023
Q1 		$180K Buy
+16,400
New +$144K ﹤0.01% 1777
2021
Q4 		– Sell
-19,900
Closed -$440K – 1854
2021
Q3 		$440K Buy
+19,900
New +$316K 0.01% 1145
2019
Q3 		– Sell
-305
Closed -$201K – 763
2019
Q2 		$201K Buy
+305
New +$1.94K 0.02% 618

Other funds holding AUPH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boothbay Fund Management's AUPH Position: Q1 2024 in Review

Boothbay Fund Management sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2024, closing a stake of 14,000 shares — an estimated $126K sold.

Boothbay Fund Management first reported a position in AUPH in Q3 2016 and held it in 11 quarters. The position peaked at $1.74M in Q4 2019. 179 funds tracked by Wall St. Rank hold AUPH as of Q1 2024.

  • Boothbay Fund Management reported no remaining Aurinia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 14,000 Aurinia Pharmaceuticals shares in Q1 2024, an estimated $126K.
  • Boothbay Fund Management first reported a position in Aurinia Pharmaceuticals in Q3 2016 and held it in 11 quarters.
  • Boothbay Fund Management's Aurinia Pharmaceuticals position peaked at $1.74M in Q4 2019.
  • 179 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.